Altre lingue Orthocell Limited

Azioni

Mercato chiuso - Australian S.E. Altri mercati azionari 07:42:03 15/05/2024			Variaz. 5gg	Var. 1 gen.
0,38 ^AUD	-5,00%		+2,70%	-7,32%

14/05	La membrana dentale Striate+ di Orthocell ottiene un tasso di successo del 98,6% nello studio clinico post-mercato; le azioni salgono del 3%.	MT
15/04	Orthocell ottiene un rimborso fiscale per la ricerca e lo sviluppo di 3 milioni di dollari australiani per l'anno fiscale 2023; le azioni salgono del 3%.	MT

Orthocell's Striate+ Dental Membrane Product Achieves 98.6% Success Rate in Post-Market Clinical Study; Shares Up 3%	14/05
Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	15/04
Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	09/04
Orthocell Completes First Stage of Remplir US Market Authorization Study	25/03
Orthocell raising $3.5 million; adds heavy hitters to register	23/02
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02
Orthocell Completes AU$3.5 Million Share Placement	22/02
Orthocell Submits Regulatory Application for Remplir in Singapore	13/02
Orthocell Limited Announces Resignation of Matthew Callahan from the Board	15/01
Orthocell Limited Appoints Kim Beazley AC as an Independent Non-Executive Director	14/01
Orthocell Completes Chair Transition Process	22/12
Orthocell Limited Announces Changes to its Board	21/12
Orthocell on the cusp of significant growth	01/11
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023	24/10/23
Orthocell Limited Announces Board Changes	24/10/23
Orthocell Limited Announces Board Changes	22/09/23
Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
Orthocell Secures Over AU$3 Million R&D Tax Rebate	21/06/23
Orthocell thrilled to welcome John Van Der Wielen as chairman	29/05/23
Orthocell Appoints Nonexecutive Chair	29/05/23

Non ci sono risultati per questa ricerca